Primary tumor location and outcomes after cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases of colorectal origin Journal Article

   


Authors: Adileh, M.; Yuval, J. B.; Walch, H. S.; Chatila, W. K.; Yaeger, R.; Garcia-Aguilar, J.; Schultz, N.; Paty, P. B.; Cercek, A.; Nash, G. M.
Article Title: Primary tumor location and outcomes after cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases of colorectal origin
Abstract: Background: The aim of this study is to evaluate outcomes in patients with peritoneal metastasis of colorectal cancer (pmCRC) who underwent cytoreductive surgery and intraperitoneal chemotherapy (CRS/IPC) in relation to the location of the primary tumor. Regional therapy, including cytoreductive surgery and intraperitoneal chemotherapy, has been associated with improved survival in patients with pmCRC. Location of the primary tumor has been shown to be prognostic in patients with metastasis. Patients and Methods: A retrospective review was performed for all patients who underwent complete cytoreduction and intraperitoneal chemotherapy from 2010 to 2017, examining patient and tumor characteristics, overall and recurrence-free survival, recurrence patterns, and tumor mutational profiles. Results: Ninety-three patients were included in the study: 49 (53%) with a right-sided and 44 (47%) with a left-sided primary tumor. Patients with a right-sided tumor had significantly shorter recurrence-free survival (median, 6.3 months; 95% CI, 4.7–8.1 months vs 12.3 months; 95% CI, 3.6–21.7 months; P = 0.02) and overall survival (median, 36.6 months; 95% CI, 26.4–46.9 months vs 83.3 months; 95% CI 44.2–122.4 months; P = 0.03). BRAF and KRAS mutations were more frequent in right-sided tumors, and APC and TP53 mutations were more frequent in left-sided tumors, which were more chromosomally instable. BRAF mutations were associated with early recurrence. Conclusions: Tumor sidedness is a predictor of oncological outcomes after CRS/IPC. Tumor sidedness and molecular characteristics should be considered when counseling patients regarding expected outcomes and when selecting or stratifying pmCRC patients for clinical trials of regional therapy. © 2020, Society of Surgical Oncology.
Journal Title: Annals of Surgical Oncology
Volume: 28
Issue: 2
ISSN: 1068-9265
Publisher: Springer  
Date Published: 2021-02-01
Start Page: 1109
End Page: 1117
Language: English
DOI: 10.1245/s10434-020-08993-7
PUBMED: 32844293
PROVIDER: scopus
PMCID: PMC7855731
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089827394&doi=10.1245%2fs10434-020-08993-7&partnerID=40&md5=90c954412c0dc317570e9929a5f2f77a
Notes: Article -- Erratum issued, see DOI: 10.1245/s10434-020-09191-1 -- Export Date: 1 February 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Philip B Paty
    496 Paty
  2. Andrea Cercek Hanjis
    351 Cercek Hanjis
  3. Rona Denit Yaeger
    315 Yaeger
  4. Garrett Nash
    261 Nash
  5. Nikolaus D Schultz
    486 Schultz
  6. Julio Garcia Aguilar
    345 Garcia Aguilar
  7. Mohammad Adileh
    12 Adileh
  8. Walid Khaled Chatila
    102 Chatila
  9. Henry Stuart Walch
    100 Walch
  10. Jonathan Benjamin Yuval
    37 Yuval
Related MSK Work